Related Experiment Video
Updated: Mar 26, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Emerging Immunotargets in Bladder Cancer
Francesco Massari1, Chiara Ciccarese, Nuno Vau
1Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale L.A. Scuro 10, 37124 Verona, Italy. fmassari79@gmail.com.
Abstract:
Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Insights
Systemic bladder cancer treatment options are limited, with chemotherapy showing modest results and targeted therapies proving ineffective. Immunotherapy, particularly PD1/PD-L1 pathway inhibition, offers a promising new direction for future treatments.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Systemic therapy for bladder cancer has been largely unchanged for decades, relying heavily on chemotherapy.
- Chemotherapy has reached its therapeutic limit, often with significant toxicity.
- Targeted therapies have shown limited efficacy in bladder cancer.
Purpose of the Study:
- To provide an overview of the current landscape of bladder cancer immunotherapy.
- To highlight the potential of novel immunotherapeutic strategies.
- To discuss the future of systemic treatment for bladder cancer.
Main Methods:
- Review of current literature on bladder cancer systemic therapy.
- Analysis of the efficacy and toxicity of chemotherapy and targeted therapies.
- Evaluation of emerging immunotherapy approaches, including checkpoint inhibition and fusion proteins.
Main Results:
- Chemotherapy offers limited benefit and considerable toxicity in bladder cancer.
- Targeted therapies have not proven effective for bladder cancer.
- Immunotherapy, specifically PD1/PD-L1 pathway inhibition, demonstrates significant promise.
- Other immunotherapies like fusion proteins are under investigation.
Conclusions:
- Immunotherapy represents the most promising future avenue for systemic bladder cancer treatment.
- PD1/PD-L1 pathway inhibitors are expected to play a major role.
- Further research into novel immunotherapy strategies is warranted.
